| Literature DB >> 24891880 |
Vincenzo Bruner1, Mariangela Atteno1, Angelo Spanò1, Raffaele Scarpa1, Rosario Peluso2.
Abstract
Biological therapies and new imaging techniques have changed the therapeutic and diagnostic approach to spondyloarthritis. In patients with axial spondyloarthritis, tumor necrosis factor α (TNFα) inhibitor treatment is currently the only effective therapy in patients for whom conventional therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) has failed. TNFα inhibitor treatment is more effective in preventing articular damage in peripheral joints than in axial ones. It is important to treat patients at an early stage of disease to reduce disease progression; moreover it is necessary to identify causes of therapy inefficacy in preventing joint damage in the axial subset.Entities:
Keywords: biological therapy; spondyloarthritis; tumor necrosis factor
Year: 2014 PMID: 24891880 PMCID: PMC4040940 DOI: 10.1177/1759720X14535512
Source DB: PubMed Journal: Ther Adv Musculoskelet Dis ISSN: 1759-720X Impact factor: 5.346